<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Afatinib: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Afatinib: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Afatinib: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="90235" href="/d/html/90235.html" rel="external">see "Afatinib: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F21288840"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Gilotrif</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871623"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Giotrif</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F20975170"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Epidermal Growth Factor Receptor (EGFR) Inhibitor;</li>
<li>
                        Antineoplastic Agent, Tyrosine Kinase Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F21008421"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6b2578e4-7b08-4e30-84aa-a8623355f370">Non–small cell lung cancer, metastatic, with nonresistant EGFR mutations</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Non–small cell lung cancer (NSCLC), metastatic, with nonresistant EGFR mutations:</b> Oral: 40 mg once daily until disease progression or unacceptable toxicity</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="34a885a1-f416-4662-9603-46fc521cff58">Non–small cell lung cancer, metastatic squamous</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Non–small cell lung cancer, metastatic squamous (previously treated):</b> Oral: 40 mg once daily until disease progression or unacceptable toxicity</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<i>Missed doses: </i>Do not take a missed dose within 12 hours of next dose.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991892"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> The manufacturer recommends using the Modification of Diet in Renal Disease (MDRD) formula to estimate the GFR.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Preexisting impairment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">eGFR &gt;30 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment is necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR 15 to 29 mL/minute/1.73 m<sup>2</sup>: Reduce starting dose to 30 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR &lt;15 mL/minute/1.73 m<sup>2</sup> and hemodialysis: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F50988853"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Preexisting mild to moderate impairment (Child-Pugh class A or B): </b> No dosage adjustment is necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Preexisting severe impairment (Child-Pugh class C): </b>There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); closely monitor and adjust dose if necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatotoxicity during treatment:</b> Withhold therapy for ≥ grade 3 hepatic dysfunction. Upon improvement to baseline or ≤ grade 1, resume therapy at 10 mg per day less than previous dose. Permanently discontinue for severe afatinib-induced hepatic impairment.</p></div>
<div class="block dot drugH1Div" id="F21008425"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Permanently discontinue for intolerability or severe reaction occurring at a dose of 20 mg daily.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Cardiovascular:</b> Permanently discontinue for symptomatic left ventricular dysfunction.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dermatologic:</b> Withhold therapy for prolonged (&gt;7 days) or intolerable grade 2 or higher cutaneous reactions. Upon improvement to baseline or ≤ grade 1, resume therapy at 10 mg per day less than previous dose. Discontinue permanently for life-threatening bullous, blistering, or exfoliating skin lesions, as well as for suspected toxic epidermal necrolysis (TEN) or Stevens-Johnson syndrome (SJS).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Gastrointestinal:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Diarrhea:</p>
<p style="text-indent:-2em;margin-left:6em;">Grade 2 that persists for ≥2 consecutive days despite antidiarrheal therapy: Interrupt therapy until fully resolves, returns to baseline, or improves to ≤ grade 1, then resume with the dose reduced by 10 mg per day less than previous dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Grade 3 or higher: Interrupt therapy until resolution to ≤ grade 1, then resume at 10 mg per day less than previous dose.</p>
<p style="text-indent:-2em;margin-left:4em;">GI perforation: Discontinue permanently.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Ocular:</b> Interrupt therapy for suspected keratitis; consider discontinuation if diagnosis of ulcerative keratitis is confirmed. Permanently discontinue for persistent ulcerative keratitis.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Pulmonary:</b> Interrupt therapy for suspected interstitial lung disease (ILD); permanently discontinue if diagnosis is confirmed.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Other toxicity: </b>Grade 3 or higher adverse reactions: Withhold therapy for ≥ grade 3 adverse reactions. Upon improvement to baseline or ≤ grade 1, resume therapy at 10 mg per day less than previous dose.</p></div>
<div class="block doe drugH1Div" id="F21008422"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F21082606"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acneiform eruption (≤90%), erythema of skin (≤90%), skin rash (≤90%), paronychia (11% to 58%), xeroderma (31%), pruritus (10% to 21%), cheilitis (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased serum potassium (11% to 30%), weight loss (17%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (75% to 96%), stomatitis (30% to 71%; grade 3: 9%; grades 3/4: 4%), decreased appetite (25% to 29%), nausea (21% to 25%), vomiting (13% to 23%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Cystitis (13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Lymphocytopenia (38%; grades 3/4: 9%), decreased white blood cell count (12%; grades 3/4: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (10% to 54%), increased serum alkaline phosphatase (34% to 51%), increased serum aspartate aminotransferase (7% to 46%), abnormal hepatic function tests (6% to 18%), increased serum bilirubin (3% to 16%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctivitis (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Decreased creatinine clearance (49%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Epistaxis (17%), rhinorrhea (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (12%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Ventricular dysfunction (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Fatigue (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Nail disease (3% to 9%), palmar-plantar erythrodysesthesia (2% to 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Severe diarrhea (5% to 6%), severe vomiting (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypokalemia (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Keratitis (≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pneumonia (7%), dyspnea (2% to 3%), interstitial pulmonary disease (≤2%), pulmonary toxicity (≤1%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Acute renal function, bullous rash, gastrointestinal perforation, local skin exfoliation, pancreatitis, physical health deterioration, respiratory failure, sepsis, skin blister, Stevens-Johnson syndrome, toxic epidermal necrolysis</p></div>
<div class="block coi drugH1Div" id="F20975172"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the manufacturer's US labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Hypersensitivity to afatinib or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F21008378"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular toxicity: Decreases from baseline in left ventricular ejection fraction (LVEF) were noted in some patients receiving afatinib. Patients with abnormal LVEF or a significant cardiac history were excluded from clinical trials; use with caution in patients with cardiac risk factors and/or decreased LVEF. Permanently discontinue in patients who develop symptomatic left ventricular dysfunction.</p>
<p style="text-indent:-2em;margin-left:4em;">• Dermatologic toxicity: Cutaneous reactions (eg, acneiform rash, erythema, rash) are common; grade 3 reactions (characterized by bullous, blistering, and exfoliating lesions) and palmar-plantar erythrodysesthesia syndrome were also seen in clinical trials. Cases of skin reactions consistent with Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported; SJS and TEN result from a mechanism that is distinct and separate from the bullous skin toxicity typically observed with EGFR inhibitor therapy. Dermatologic toxicity may require therapy interruption and dosage reduction; discontinue if life-threatening bullous, blistering, or exfoliating lesions occur or for suspected SJS or TEN. Patients should be cautioned to avoid sun exposure and/or utilize adequate sun protection.</p>
<p style="text-indent:-2em;margin-left:4em;">• GI toxicity: In clinical trials, diarrhea (including grade 3 and 4 events) and stomatitis frequently occurred in patients treated with afatinib; diarrhea was observed in the majority of patients and typically appeared within the first 6 weeks of therapy. Dehydration and renal impairment may occur as a consequence of diarrhea; monitor closely. Patients may require antidiarrheal therapy (eg, loperamide); initiate at the onset of diarrhea and continue until free of loose bowel movements for 12 hours. May necessitate therapy interruption and dosage reduction. GI perforations (some fatal) have been reported; risk may be increased in older patients, patients with a history of GI ulceration, underlying diverticular disease or bowel metastases, or with concomitant use of corticosteroids, NSAIDs, or anti-angiogenic agents. Permanently discontinue afatinib in patients who develop GI perforation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatitis B virus screening: The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen (HBsAg), hepatitis B core antibody (anti-HBc), total Ig or IgG, and antibody to hepatitis B surface antigen (anti-HBs) prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatotoxicity: Hepatic function test abnormalities (some fatal) were observed in clinical trials. Monitor liver function tests periodically; may require therapy interruption and dosage reduction. Discontinue if severe hepatic impairment occurs during therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular toxicity: Keratitis (including rare grade 3 events) was reported rarely in clinical trials; monitor for signs/symptoms of keratitis (eg, acute or worsening eye inflammation, blurred vision, eye pain, lacrimation, light sensitivity, red eye). Interrupt therapy in patients with suspected keratitis; if diagnosis of ulcerative keratitis is confirmed, interrupt or discontinue afatinib (permanently discontinue for persistent ulcerative keratitis). Use with caution in patients with a history of keratitis, severe dry eye, ulcerative keratitis, or who wear contact lenses (risk factor for keratitis and ulceration).</p>
<p style="text-indent:-2em;margin-left:4em;">• Paronychia: Paronychia requiring dose reduction and discontinuation of therapy has been observed.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pulmonary toxicity: Interstitial lung disease (ILD) or ILD-like reactions occurred in a small percentage of patients treated with afatinib (some fatal). ILD incidence appeared to be higher in Asian compared with non-Asian patients. Monitor closely for signs/symptoms of ILD (eg, acute respiratory distress syndrome, allergic alveolitis, lung infiltration, pneumonitis). Interrupt therapy for suspected ILD; discontinue therapy with confirmed diagnosis.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use in severe hepatic impairment (Child-Pugh class C) has not been studied; closely monitor patients with severe impairment, may require dosage adjustments if not tolerated.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Dosage reduction is recommended in patients with severe renal impairment (eGFR 15 to 29 mL/minute/1.73 m<sup>2</sup>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage forms specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Lactose: Formulation may contain lactose.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: For first-line therapy, safety and efficacy have not been established in patients with non-small cell lung cancer whose tumors express resistant EGFR mutations. Information on EGFR mutation testing is available at <a href="/external-redirect?target_url=http%3A%2F%2Fwww.fda.gov%2FCompanionDiagnostics&amp;token=SHauxSdf9qNc6lLK16E8IPc%2BkYYsON95PtA1EteUbfjUoJYJ%2BuveJw2PtFUTXMkK&amp;TOPIC_ID=90144" target="_blank">www.fda.gov/CompanionDiagnostics</a>. Increased mortality has been observed in a clinical trial evaluating afatinib in combination with vinorelbine for HER2-positive metastatic breast cancer (not an approved use). This combination was also associated with a higher incidence of adverse events (eg, diarrhea, rash), as well as fatalities due to infection and cancer progression. Afatinib should not be used in combination with vinorelbine for the treatment of HER2-positive metastatic breast cancer.</p></div>
<div class="block foc drugH1Div" id="F21317419"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Gilotrif: 20 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Gilotrif: 30 mg, 40 mg [contains fd&amp;c blue #2 (indigotine,indigo carmine)]</p></div>
<div class="block geq drugH1Div" id="F21008361"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F23613360"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Gilotrif Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $457.93</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $457.93</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $457.93</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871624"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Giotrif: 20 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Giotrif: 30 mg, 40 mg [contains fd&amp;c blue #2 (indigotine,indigo carmine)]</p></div>
<div class="block adm drugH1Div" id="F21008428"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral: Administer ≥1 hour before or 2 hours after a meal. Do not take a missed dose within 12 hours of the next dose.</p></div>
<div class="block hazard drugH1Div" id="F49104413"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block use drugH1Div" id="F20974712"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Non-small cell lung cancer, metastatic, EGFR mutation-positive:</b> First-line treatment of metastatic non-small cell lung cancer (NSCLC) in patients whose tumors have nonresistant epidermal growth factor receptor (EGFR) mutations as detected by an approved test.</p>
<p style="text-indent:-2em;margin-left:4em;">Limitations of use: Safety and efficacy have not been established in patients whose tumors express resistant EGFR mutations.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Non-small cell lung cancer, metastatic squamous:</b> Treatment of previously treated metastatic squamous cell NSCLC that has progressed following platinum-based chemotherapy.</p></div>
<div class="block mst drugH1Div" id="F21008359"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Afatinib may be confused with abemaciclib, acalabrutinib, Afinitor, alectinib, alpelisib, axitinib, ceritinib, crizotinib, dacomitinib, enasidenib, erlotinib, fedratinib, fostamatinib, gefitinib, neratinib</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F21122184"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of BCRP/ABCG2, P-glycoprotein/ABCB1 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F21122182"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asciminib: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elacestrant: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erdafitinib: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). Management: If coadministration with these narrow therapeutic index/sensitive P-gp substrates is unavoidable, separate erdafitinib administration by at least 6 hours before or after administration of these P-gp substrates.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Futibatinib: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gilteritinib: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lasmiditan: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumacaftor and Ivacaftor: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (High risk with Inhibitors or Inducers). Lumacaftor and Ivacaftor may decrease the serum concentration of P-glycoprotein/ABCB1 Substrates (High risk with Inhibitors or Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxsalen (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Methoxsalen (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mitapivat: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nelfinavir: May increase the serum concentration of Afatinib. Management: Monitor for signs and symptoms of afatinib toxicity when these agents are combined. Consider administering nelfinavir simultaneously with, or after, the dose of afatinib. If the combination is not tolerated, consider reducing the afatinib dose by 10 mg.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pacritinib: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of Afatinib. Management: Increase the afatinib dose by 10 mg as tolerated in patients requiring chronic coadministration of P-gp inducers with afatinib. Reduce afatinib dose back to the original afatinib dose 2 to 3 days after discontinuation of the P-gp inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of Afatinib. Management: If combined, administer the P-gp inhibitor simultaneously with, or after, the dose of afatinib. Monitor closely for signs and symptoms of afatinib toxicity and if the combination is not tolerated, reduce the afatinib dose by 10 mg.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">PHENobarbital: May decrease the serum concentration of Afatinib. Management: Consider increasing the afatinib dose by 10 mg as tolerated in patients requiring chronic coadministration of phenobarbital with afatinib. Reduce afatinib dose back to the original afatinib dose 2 to 3 days after discontinuation of phenobarbital.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pretomanid: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Primidone: May decrease the serum concentration of Afatinib. Management: Consider increasing the afatinib dose by 10 mg as tolerated in patients requiring chronic coadministration of phenobarbital with afatinib. Reduce afatinib dose back to the original afatinib dose 2 to 3 days after discontinuation of phenobarbital.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Saquinavir: May increase the serum concentration of Afatinib. Management: Monitor for signs and symptoms of afatinib toxicity when these agents are combined. Consider administering saquinavir simultaneously with, or after, the dose of afatinib. If the combination is not tolerated, consider reducing the afatinib dose by 10 mg.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sotorasib: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). Management: Consider avoiding use of sotorasib and narrow therapeutic index/sensitive P-gp substrates. If combined use is unavoidable, monitor for increased toxicities of the substrate and consider a decrease in the substrate dosage.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sparsentan: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): May increase the serum concentration of Afatinib. Management: Monitor for signs and symptoms of afatinib toxicity when these agents are combined. Consider administering tacrolimus simultaneously with, or after, the dose of afatinib. If the combination is not tolerated, consider reducing the afatinib dose by 10 mg.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Taurursodiol: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F21008380"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Administration with a high-fat meal decreases C<sub>max</sub> by 50% and AUC by 39% as compared to the fasted state. Management: Take at least 1 hour before or 2 hours after a meal.</p></div>
<div class="block rep_considerations drugH1Div" id="F49057007"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Women of reproductive potential should use highly effective contraception during therapy and for at least 2 weeks after the last afatinib dose.</p></div>
<div class="block pri drugH1Div" id="F21008363"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on animal reproduction studies and on the mechanism of action, afatinib may cause fetal harm if used during pregnancy.</p></div>
<div class="block brc drugH1Div" id="F21008365"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if afatinib is present into breast milk. Due to the potential for serious adverse reactions in the breastfed infant, the manufacturer recommends against breastfeeding during therapy and for at least 2 weeks after the last afatinib dose.</p></div>
<div class="block mop drugH1Div" id="F21008431"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">EGFR mutation status (for first-line therapy); liver and renal function (periodically). Hepatitis B virus screening with hepatitis B surface antigen (HBsAg), hepatitis B core antibody (anti-HBc), total Ig or IgG, and antibody to hepatitis B surface antigen (anti-HBs) prior to beginning systemic anticancer therapy (ASCO [Hwang 2020]). Consider left ventricular ejection fraction assessment prior to and during therapy in patients with cardiac risk factors or conditions that may impair left ventricular function. Monitor for skin toxicity, diarrhea, signs/symptoms of dehydration; monitor for signs/symptoms of interstitial lung disease (eg, acute respiratory distress syndrome, allergic alveolitis, lung infiltration, pneumonitis) and keratitis (eg, acute or worsening eye inflammation, blurred vision, eye pain, lacrimation, light sensitivity, red eye). Monitor adherence.</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular monitoring: Comprehensive assessment prior to treatment including a history and physical examination, screening for cardiovascular disease risk factors such as hypertension, diabetes, dyslipidemia, obesity, and smoking (ASCO [Armenian 2017]; ESC [Lyon 2022]).</p></div>
<div class="block pha drugH1Div" id="F21008400"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Afatinib is a highly selective tyrosine kinase inhibitor that covalently binds to EGFR (ErbB1), HER2 (ErbB2), and HER4 (ErbB4) to irreversibly inhibit tyrosine kinase autophosphorylation and downregulate ErbB signaling. Certain EGFR mutations (including nonresistant mutations) result in increased receptor autophosphorylation, leading to receptor activation (sometimes without ligand binding), and may support NSCLC cell proliferation. Nonresistant mutations occur in exons constituting the EGFR kinase domain that lead to increased receptor activation; efficacy is predicted by tumor shrinkage and/or inhibition of cellular proliferation or EGFR tyrosine kinase phosphorylation. The most common mutations are exon 21 L858R substitutions and exon 19 deletions. Afatinib inhibits autophosphorylation and/or proliferation (in vitro) in cell lines expressing both wild-type EGFR and selected EGFR exon 19 deletion mutations, exon 21 L858R mutations, or other less common nonresistant mutations. Additionally, afatinib inhibited <i>in vitro</i> proliferation of cell lines overexpressing HER2.</p></div>
<div class="block phk drugH1Div" id="F21008402"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Decreased with high-fat meals</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~95%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Covalently adducted to proteins and nucleophilic small molecules (minimal enzymatic metabolism) (Wind 2013); ~2% of a dose is metabolized by FMO3</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Tablets: 92% (as compared to an oral solution)</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 37 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: 2 to 5 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces (85%); urine (4%); primarily as unchanged drug</p></div>
<div class="block phksp drugH1Div" id="F51219912"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: A small pharmacokinetic study demonstrated a 50% increase and a 22% increase in mean AUC<sub>inf</sub> in patients with severe renal impairment (eGFR 15 to 29 mL/minute/1.73 m<sup>2</sup>) and moderate renal impairment (eGFR 30 to 59 mL/minute/1.73 m<sup>2</sup>), respectively, as compared to patients with normal renal function (eGFR 90 mL/minute/1.73 m<sup>2</sup> or higher). C<sub>max</sub> was 22% higher in patients with severe renal impairment and was comparable in patients with moderate renal impairment and patients with normal renal function.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F23777301"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Giotrif</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Afatinib eczane | Giotrif</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Giotrif</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Giotrif</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Afatin | Atanib</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Giotrif</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Giotrif</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Giotrif</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Giotrif</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Giotrif</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Giotrif</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Giotrif</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Giotrif</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Afatinib | Giotrif</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Giotrif</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Giotrif</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Giotrif</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Giotrif</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Giotrif</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Giotrif</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Giotrif</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Giotrif</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Giotrif</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Giotrif</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Giotrif</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Giotrif</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Afadel | Afanat | Afayro | Xovoltib</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Giotrif</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Giotrif</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Giotrif</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Giotrif</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Giotrif</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Giotrif</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Giotrif</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Giotrif</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Giotrif</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Giotrif</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Giotrif</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Giotrif</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Giotrif</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Giotrif</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Giotrif</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Giotrif</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Giotrif</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Giotrif</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Giotrif</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Giotrif</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Giotrif</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Giotrif</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Giotrif</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Giotrif</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Giotrif</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Giotrif</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Giotrif</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Giotrif</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Giotrif</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Giotrif</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Giotrif</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  &lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27918725">
<a name="27918725"></a>Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol</i>. 2017;35(8):893-911. doi:10.1200/JCO.2016.70.5400<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/afatinib-drug-information/abstract-text/27918725/pubmed" id="27918725" target="_blank">27918725</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Gilotrif (afatinib) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; April 2022.</div>
</li>
<li>
<div class="reference">
                  Giotrif (Afatinib) [product monograph]. Burlington, Ontario, Canada: Boehringer Ingelheim (Canada) Ltd; June 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32658626">
<a name="32658626"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. Published online July 27, 2020. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/afatinib-drug-information/abstract-text/32658626/pubmed" id="32658626" target="_blank">32658626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23816963">
<a name="23816963"></a>Katakami N, Atagi S, Goto K, et al. LUX-Lung 4: A Phase II Trial of Afatinib in Patients With Advanced Non-Small-Cell Lung Cancer Who Progressed During Prior Treatment With Erlotinib, Gefitinib, or Both. <i>J Clin Oncol</i>. 2013;31(27):3335-3341.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/afatinib-drug-information/abstract-text/23816963/pubmed" id="23816963" target="_blank">23816963</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23506519">
<a name="23506519"></a>Lacouture ME, Schadendorf D, Chu CY, et al. Dermatologic Adverse Events Associated With Afatinib: An Oral Erbb Family Blocker. <i>Expert Rev Anticancer Ther</i>. 2013;13(6):721-728.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/afatinib-drug-information/abstract-text/23506519/pubmed" id="23506519" target="_blank">23506519</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36017568">
<a name="36017568"></a>Lyon AR, López-Fernández T, Couch LS, et al; ESC Scientific Document Group. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). <i>Eur Heart J.</i> 2022;43(41):4229-4361. doi:10.1093/eurheartj/ehac244<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/afatinib-drug-information/abstract-text/36017568/pubmed" id="36017568" target="_blank">36017568</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26324367">
<a name="26324367"></a>Masters GA, Temin S, Azzoli CG. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update [published correction appears in <i>J Clin Oncol</i>. 2016;34(11):1287]. <i>J Clin Oncol</i>. 2015;33(30):3488-3515.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/afatinib-drug-information/abstract-text/26324367/pubmed" id="26324367" target="_blank">26324367</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22452896">
<a name="22452896"></a>Miller VA, Hirsh V, Cadranel J, et al. Afatinib versus Placebo for Patients With Advanced, Metastatic Non-Small-Cell Lung Cancer After Failure of Erlotinib, Gefitinib, or Both, and One or Two Lines of Chemotherapy (LUX-Lung 1): A Phase 2b/3 Randomised Trial. <i>Lancet Oncol</i>. 2012;13(5):528-539.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/afatinib-drug-information/abstract-text/22452896/pubmed" id="22452896" target="_blank">22452896</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23816960">
<a name="23816960"></a>Sequist LV, Yang JC, Yamamoto N, et al. Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations. <i>J Clin Oncol</i>. 2013;31(27):3327-3334.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/afatinib-drug-information/abstract-text/23816960/pubmed" id="23816960" target="_blank">23816960</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26156651">
<a name="26156651"></a>Soria JC, Felip E, Cobo M, et al. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. <i>Lancet Oncol.</i> 2015;16(8):897-907.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/afatinib-drug-information/abstract-text/26156651/pubmed" id="26156651" target="_blank">26156651</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23293114">
<a name="23293114"></a>Vermorken JB, Rottey S, Ehrnrooth E, et al. A Phase 1b, Open-Label Study to Assess the Safety of Continuous Oral Treatment With Afatinib In Combination With Two Chemotherapy Regimens: Cisplatin Plus Paclitaxel and Cisplatin Plus 5-Fluorouracil, in Patients With Advanced Solid Tumors. <i>Ann Oncol</i>. 2013;24(5):1392-1400.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/afatinib-drug-information/abstract-text/23293114/pubmed" id="23293114" target="_blank">23293114</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23813493">
<a name="23813493"></a>Wind S, Schmid M, Erhardt J, et al. Pharmacokinetics of Afatinib, a Selective Irreversible ErbB Family Blocker, in Patients With Advanced Solid Tumours. <i>Clin Pharmacokinet</i>. 2013;52(12):1101-1109.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/afatinib-drug-information/abstract-text/23813493/pubmed" id="23813493" target="_blank">23813493</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23816967">
<a name="23816967"></a>Yang JC, Hirsh V, Schuler M, et al. Symptom Control and Quality of Life in LUX-Lung 3: A Phase III Study of Afatinib or Cisplatin/Pemetrexed in Patients With Advanced Lung Adenocarcinoma With EGFR Mutations. <i>J Clin Oncol</i>. 2013;31(27):3342-3350.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/afatinib-drug-information/abstract-text/23816967/pubmed" id="23816967" target="_blank">23816967</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23506556">
<a name="23506556"></a>Yang JC, Reguart N, Barinoff J, et al. Diarrhea Associated With Afatinib: An Oral ErbB Family Blocker. <i>Expert Rev Anticancer Ther</i>. 2013;13(6):729-736.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/afatinib-drug-information/abstract-text/23506556/pubmed" id="23506556" target="_blank">23506556</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22452895">
<a name="22452895"></a>Yang JC, Shih JY, Su WC, et al. Afatinib for Patients With Lung Adenocarcinoma and Epidermal Growth Factor Receptor Mutations (LUX-Lung 2): A Phase 2 Trial. <i>Lancet Oncol</i>. 2012;13(5):539-548.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/afatinib-drug-information/abstract-text/22452895/pubmed" id="22452895" target="_blank">22452895</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 90144 Version 198.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
